Abstract:Purpose: Glial fibrillary acidic protein serves as a biomarker indicative of astroglial injury, particularly following instances of severe traumatic brain injury. This study aims to evaluate variations in serum glial fibrillary acidic protein levels within the first 3 days and their correlation with outcomes in patients with severe traumatic brain injury. Subjects and methods: Thirty-nine patients with severe traumatic brain injury were enrolled in the study. Their blood samples were collected at six distinct time points: T0 (upon admission), T1, T2, T3, T4, and T5 (6-, 12-, 24-, 48-, and 72-h post-admission, respectively). The blood samples were run for the quantification of serum glial fibrillary acidic protein levels and other biochemical tests. All patients were closely watched and the outcomes at discharge were evaluated. Results: Glial fibrillary acidic protein levels tend to increase gradually from the time of admission to 48 h post-admission and then decrease at 72 h post-admission. Glial fibrillary acidic protein T2 is correlated with Acute Physiology and Chronic Health Evaluation II score, lactate, Simplified Acute Physiology Score II score and outcome. Glial fibrillary acidic protein max correlated with lactate, Acute Physiology and Chronic Health Evaluation II score, Simplified Acute Physiology Score II score, and outcome. Glasgow Coma Score at admission and glial fibrillary acidic protein T2 (OR = 1.034; p = 0.025), T3 (OR = 1.029; p = 0.046), T4 (OR = 1.006; p = 0.032), T5 (OR = 1.012; p = 0.048) and glial fibrillary acidic protein max (OR = 1.005; p = 0.010) were independent factors that have significant prognostic value in mortality in patients with severe traumatic brain injury. The predictive model in predicting mortality had the highest area under the curve based on glial fibrillary acidic protein T2 and Glasgow Coma Score T0 with an area under the curve of 0.904 and p < 0.001. In the multivariable regression model, glial fibrillary acidic protein max was associated with Glasgow score (p < 0.001; VIF = 1.585), lactate T0 (p = 0.024; VIF = 1.163), Acute Physiology and Chronic Health Evaluation II score (p = 0.037; VIF = 1.360), and Rotterdam score (p = 0.044; VIF = 1.713). Conclusion: Glial fibrillary acidic protein levels tend to increase gradually from the time of admission to 48 h post-admission then decreases at 72 h post-admission. Glial fibrillary acidic protein T2, T3, T4, T5, and glial fibrillary acidic protein max were independent factors with significant prognostic mortality values in patients with severe traumatic brain injury.

The Change and Clinical Significance of Serum Aquaporin-4 and Pnf-H in Patients with Moderate and Severe Traumatic Brain Injury

Complement cascade on severe traumatic brain injury patients at the chronic unconscious stage: implication for pathogenesis.

Change in Plasma Microparticle Procoagulant Activity after Traumatic Brain Injury

Early Changes of Endothelin, Nitric Oxide and Arginine-Vasopressin in Patients with Acute Cerebral Injury.

Serum Albumin And Prealbumin Predict The Poor Outcome Of Traumatic Brain Injury

Dynamically Monitoring Tissue Factor and Tissue Factor Pathway Inhibitor Following Secondary Brain Injury

Relationship between cerebrospinal fluidα-Synuclein and prognosis of patients with traumatic brain injury

Influence and Relationship Between Mild Hypothermia and Immune Function and Acquired Pneumonia in Severe Traumatic Brain Injury Patient

Expression of heat shock protein 70 and Annexin A1 in serum of patients with acutely severe traumatic brain injury

The Relationship Between the Change of Aquaporin4,brain Edema and Neuronal Function Score of Fluid Percussion Brain Injury in Rats

Dynamic Changes of Serum Glial Fibrillary Acidic Protein Content in Patients with Brain Injury and Their Cllnical Significance

Expression of Aquaporin 4 in Contused Brain Tissue and Its Relationship with Brain Edema

The Significance of the Detection of Serum Lactate Dehydrogenase, Hypersensitive C-Reactive Protein, and N-Terminal Pro-Brain Natriuretic Peptide for the Evaluation of the Severity and Progression of Pediatric Patients with Traumatic Brain Injury

Change of Concentrations of Serum Cyclophilin A in Patients with Traumatic Brain Injury and its Clinical Significance

BNP and NT-proBNP Concentrations in Paired cerebrospinal Fluid and Plasma Samples of Patients with Traumatic Brain Injury

Potential Prognostic Marker in Craniocerebral Injuries

Change of Serum Levels of Thioredoxin in Patients with Severe Traumatic Brain Injury.

Changes in the levels of serum glial fibrillary acidic protein and the correlation with outcomes in severe traumatic brain injury patients

Determination of Serum Prealbumin and Retinol-Binding Protein in Patients with Acute Traumatic Brain Injury and Its Clinical Significance

Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI

Role of Α-Ii-spectrin Breakdown Products in the Prediction of the Severity and Clinical Outcome of Acute Traumatic Brain Injury.